Full-Time
Biomanufacturing services for cell and gene therapy
$65k - $80k/yr
Senior
Frederick, MD, USA + 1 more
More locations: Bethesda, MD, USA
Full time on-site client presence; Willingness to travel up to 100% or as required to support project and business needs.
Project Farma specializes in biomanufacturing, focusing on cell and gene therapy. They develop and implement strategies for advanced therapy facilities, helping clients create treatments that modify genes to address diseases. Their services encompass the entire lifecycle of biomanufacturing projects, including facility construction, validation, quality assurance, regulatory compliance, and automation. Project Farma distinguishes itself by offering comprehensive, turnkey solutions that ensure facilities meet Good Manufacturing Practices (GMP), which is essential for producing safe therapies. They generate revenue through consulting and project management fees, serving a diverse clientele that includes biotech startups, pharmaceutical companies, and research institutions. Additionally, Project Farma emphasizes philanthropy and professional development, highlighted by their annual PF Cares Weekend, which focuses on skill enhancement and improving patient outcomes.
Company Size
51-200
Company Stage
Acquired
Total Funding
N/A
Headquarters
Chicago, Illinois
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Paid Vacation
Company Paid Maternity and Parental Leave
Continuing Education Assistance
PerkinElmer, a global leader in analytical solutions and specialized services for (bio)pharma, applied and food markets, today announced the acquisiti
PerkinElmer acquires Project Farma, expanding its OneSource professional services offering for the life sciences industry.
Project Farma formed its relationship with Feed My Starving Children back in 2018, where its team spent an afternoon processing various foods for dehydrating, canning, and other forms of preservation.